Pediatr. praxi. 2014;15(4):191-193

Mononucleosis - evidence based diagnostics and therapy

MUDr.Jan Pavelka
Klinika dětských infekčních nemocí, FN Brno
Lékařská fakulta Masarykovy univerzity, Brno

Epstein–Barr virus is the most common ethiology of mononucleosis syndrome. Almost every man is infected during lifetime. More than

a half of the cases are asymptomatic. Lifelong carriage ensues with intermittent episodes of reactivation and virus shedding in saliva.

Treatment is symptomatic. Causal treatment is not available. Fat restriction in diet is obsolete. Hepatoprotective drugs have similar

efficacy to placebo. Patients with normal immunity recover in 2 to 3 weeks. Restriction of a physical exercise for more than 7 weeks in

recovered patients is not justified.

Keywords: EBV, Epstein–Barr, mononucleosis, diet, treatment, management

Published: September 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pavelka J. Mononucleosis - evidence based diagnostics and therapy. Pediatr. praxi. 2014;15(4):191-193.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Luzuriaga K, Sullivan J. Infectious Mononucleosis. N Engl J Med. 2010; 362: 1993-2000. Go to original source... Go to PubMed...
    2. Heath C, Brodsky A, Potolsky A. Infectious mononucleosis in a general population. Am J Epidemiol. 1972; 95(1): 46-52. Go to original source... Go to PubMed...
    3. Hess R. RoutineEpstein-Barr Virus Diagnostics from the Laboratory Perspective: Still Challenging after 35 Years. J Clin Microbiol. 2004; 42(8): 3381-3387. Go to original source... Go to PubMed...
    4. Thorley-Lawson D, Gross A. Persistence of the Epstein-Barr Virus and the Origins of Associated Lymphomas. N Engl J Med. 2004; 350: 1328-1337. Go to original source... Go to PubMed...
    5. Johannsen E, Kenneth M. Epstein-Barr Virus (Infectious Mononucleosis, Infectious Mononucleosis-Associated Malignant Diseases, and Other Diseases). In: Mandell, Douglas and Bennett´s Principles and Practice of Infectious Diseases, 7th ed. Philadelphia: Churchill Livingstone Elsevier. 2010; 1989-2010. Go to original source...
    6. Laichalk L, Hochberg D, Babcock G, et al. The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity 2002; 16(5): 745-754. Go to original source... Go to PubMed...
    7. Straus S, Cohen J, Tosato G, et al. Epstein-Barr Virus Infections: Biology, Pathogenesis, and Management. Ann Intern Med. 1993; 118(1): 45-58. Go to original source... Go to PubMed...
    8. Cohen J. Epstein-Barr Virus Infection. N Engl J Med. 2000; 343: 481-492. Go to original source... Go to PubMed...
    9. Putukian M, O'Connor F, Stricker P, et al. Mononucleosis and athletic participation: an evidence-based subject review. Clin J Sport Med. 2008; 18: 309-315. Go to original source... Go to PubMed...
    10. Fisher R, Boyce T. Infectious Mononucleosis and Mononucleosis-like Syndromes. In: Moffet's Pediatric Infectious Diseases: A Problem-Oriented Approach, 4th Edition. 2005; 49-61.
    11. Field P, Dwyer D. Difficulties with the serologic diagnosis of infectious mononucleosis: a review of the rcpa quality assurance programs. Pathology 1996; 28: 270-276. Go to original source... Go to PubMed...
    12. Johnson D, Cunha B. Epstein-Barr virus serology. Infect Dis Pract. 1995; 19: 26-27.
    13. Staňková M. Infekční mononukleóza a další nemoci vyvolané virem Epsteina a Barrové. In Beneš J, et al. Infekční lékařství. Praha: 2009; 183-184.
    14. McIntyre N. The general management of liver disease. In: Oxford textbook of clinical hepatology 1992; 1335-1339.
    15. Chalupa P, Husa P. Infekce jater, žlučových cest a pankreatu. In Beneš J. et al. Infekční lékařství. Praha: 2009; 454-464.
    16. Vaništa J. Virové hepatitidy. In: Hrodek O, Vavřinec J, et al. Pediatrie. Praha: 2002; 631-638.
    17. Sobotka L. Dietní opatření u interních chorob. In Bureš J, Horáček J, et al. Základy vnitřního lékařství, 2003; 670-677.
    18. Brůha R. Hepatoprotektiva. Klin Farmakol Farm. 2006; 20: 154-157.
    19. Thompson M, Kurzrock R. Epstein-Barr Virus and Cancer. Clin Cancer Res. 2004; 10: 803-821. Go to original source... Go to PubMed...
    20. Gruhne B, Sompallae R, Masucci M. Three Epstein-Barr virus latency proteins independently promotegenomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene 2009; 28: 3997-4008. Go to original source... Go to PubMed...
    21. Booth C, Gilmour K, Veys P, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 2011; 117(1): 53-62. Go to original source... Go to PubMed...
    22. Janka G. Hemophagocytic syndromes. BloodRev. 2007; 21(5): 245-253. Go to original source... Go to PubMed...
    23. Obořilová A, Mayer J, Pavlík P, et al. Hemofagocytární syndrom (Kazuistika a review literatury). Vnitř. Lék. 2003; 3: 210-216.
    24. Kelesidis T, Humphries R, Terashita D, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Los Angeles County. J Med Virol. 2012; 84(5): 777-785. Go to original source... Go to PubMed...
    25. Engleberg N. Chronic Fatigue Syndrome. In: Mandell, Douglas and Bennett´s Principles and Practice of Infectious Diseases, 7th ed. Philadelphia: Churchill Livingstone Elsevier 2010; 1897-1904. Go to original source...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.